Senseonics Holdings, a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, entered into a $50 million loan facility with Hercules Capital.
X4 Pharmaceuticals, a provider and developer of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, closed a $115 million loan facility with Hercules Capital. The company also announced that it drew down $22.5 million upon the transaction’s closing.
COMPASS Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, entered into a term loan agreement with Hercules Capital for up to $50 million.
AmplifyBio augmented its balance sheet with non-dilutive debt financing, whereby it may borrow a principal amount of up to $50 million from Hercules Capital.
Replimune Group, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, obtained a $200 million non-dilutive term loan facility from Hercules Capital.
Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.
Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.
Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, obtained a $200 million term loan facility from Hercules Capital.
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.
Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.